Summary

GAO reviewed the Department of Health and Human Services, Food and Drug Administration's (FDA) new rule on the use of ozone-depleting substances and the removal of essential use designation (epinephrine). GAO found that (1) the final rule removes epinephrine used in oral pressurized metered-dose inhalers from FDA's list of essential-use ozone-depleting substances that have been exempt from the Clean Air Act restrictions on their use; and (2) FDA complied with applicable requirements in promulgating the rule.